As a company formed with venture capital funding more than 25 years ago, they understand the challenges faced by early-stage biotechnology companies. In 2004, they announced the formation of Amgen Ventures, their corporate venture capital fund. With an initial investment of $100 million, the fund is designed to provide emerging biotechnology companies with resources to develop pioneering discoveries focused on human therapeutics. Amgen Ventures reflects Amgen’s commitment to helping patients by transforming cutting-edge scientific discoveries into novel treatments for serious illness.
| Company | Date | Round | Size | Participants |
| Trinity Biosystems | 11/09 | Unattributed | $7.5M | 5 |
| Epizyme | 10/09 | Series B | $32M | 5 |
| Calistoga | 6/09 | Series B | $30M | 4 |
| Miragen Therapeutics | 6/09 | Series B | $4M | 3 |
| Calistoga Pharmaceuticals | 5/09 | Series B | $30M | 4 |
| InteKrin | 8/08 | Series C | $18.5M | 7 |
